#begin document (en_3322.txt); part 000
en_3322.txt	0	0	The	DT	(TOP(NP*	-	-	-	-	*	-
en_3322.txt	0	1	Tuberculosis	NNP	*	-	-	-	-	*	-
en_3322.txt	0	2	Front	NNP	*))	-	-	-	-	*	-

en_3322.txt	0	0	BERLIN	NNP	(TOP(S(NP*	-	-	-	-	*	-
en_3322.txt	0	1	–	NNP	*)	-	-	-	-	*	-
en_3322.txt	0	2	This	DT	*	-	-	-	-	*	-
en_3322.txt	0	3	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	6	good	JJ	*	-	-	-	-	*	-
en_3322.txt	0	7	decade	NN	*)	-	-	-	-	*	-
en_3322.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	10	fight	NN	*)	-	-	-	-	*	-
en_3322.txt	0	11	against	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	12	tuberculosis	NN	(NP*)))))))	-	-	-	-	*	-
en_3322.txt	0	13	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	We	PRP	(TOP(S(NP*)	-	-	-	-	*	(0)
en_3322.txt	0	1	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	2	likely	JJ	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	3	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	4	achieve	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	6	United	NNP	*	-	-	-	-	*	-
en_3322.txt	0	7	Nations	NNPS	*	-	-	-	-	*	-
en_3322.txt	0	8	Millennium	NNP	*	-	-	-	-	*	-
en_3322.txt	0	9	Development	NNP	*	-	-	-	-	*	-
en_3322.txt	0	10	Goal	NNP	*)	-	-	-	-	*	-
en_3322.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	12	cutting	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	13	TB	NN	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	14	prevalence	NN	*)	-	-	-	-	*	-
en_3322.txt	0	15	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	16	mortality	NN	*))))))))	-	-	-	-	*	-
en_3322.txt	0	17	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	18	half	NN	(NP*))	-	-	-	-	*	-
en_3322.txt	0	19	by	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	20	2015	CD	(NP*))	-	-	-	-	*	-
en_3322.txt	0	21	,	,	*	-	-	-	-	*	-
en_3322.txt	0	22	from	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	23	1990	CD	(NP*	-	-	-	-	*	-
en_3322.txt	0	24	levels	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	25	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	At	IN	(TOP(S(S(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	1	least	JJS	*	-	-	-	-	*	-
en_3322.txt	0	2	a	DT	*	-	-	-	-	*	-
en_3322.txt	0	3	dozen	NN	*)	-	-	-	-	*	-
en_3322.txt	0	4	new	JJ	*	-	-	-	-	*	-
en_3322.txt	0	5	vaccines	NNS	*	-	-	-	-	*	-
en_3322.txt	0	6	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	7	drug	NN	*	-	-	-	-	*	-
en_3322.txt	0	8	candidates	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	9	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	11	clinical	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	12	trials	NNS	*))))	-	-	-	-	*	-
en_3322.txt	0	13	,	,	*	-	-	-	-	*	-
en_3322.txt	0	14	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	15	the	DT	(S(NP*	-	-	-	-	*	-
en_3322.txt	0	16	World	NNP	*	-	-	-	-	*	-
en_3322.txt	0	17	Health	NNP	*	-	-	-	-	*	-
en_3322.txt	0	18	Organization	NNP	*)	-	-	-	-	*	-
en_3322.txt	0	19	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	20	endorsed	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	21	a	DT	(NP(NP*	-	-	-	-	*	(1
en_3322.txt	0	22	new	JJ	*	-	-	-	-	*	-
en_3322.txt	0	23	diagnostic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	24	test	NN	*)	-	-	-	-	*	-
en_3322.txt	0	25	called	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	26	the	DT	(S(NP*	-	-	-	-	*	-
en_3322.txt	0	27	GeneXpert	NNP	*)))))))	-	-	-	-	*	1)
en_3322.txt	0	28	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	This	DT	(TOP(S(NP*	-	-	-	-	*	-
en_3322.txt	0	1	progress	NN	*)	-	-	-	-	*	-
en_3322.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	3	all	PDT	(ADJP(ADVP*	-	-	-	-	*	-
en_3322.txt	0	4	the	DT	*	-	-	-	-	*	-
en_3322.txt	0	5	more	RBR	*)	-	-	-	-	*	-
en_3322.txt	0	6	important	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	7	given	VBN	(PP*	-	-	-	-	*	-
en_3322.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	9	complacency	NN	*)	-	-	-	-	*	-
en_3322.txt	0	10	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	11	led	VBD	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	12	to	TO	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	14	complete	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	standstill	NN	*)	-	-	-	-	*	-
en_3322.txt	0	16	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	17	research	NN	(NP*	-	-	-	-	*	-
en_3322.txt	0	18	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	19	development	NN	*))	-	-	-	-	*	-
en_3322.txt	0	20	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	21	new	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	22	TB	NN	*	-	-	-	-	*	-
en_3322.txt	0	23	interventions	NNS	*))	-	-	-	-	*	-
en_3322.txt	0	24	toward	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	25	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	26	end	NN	*)	-	-	-	-	*	-
en_3322.txt	0	27	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	28	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	29	twentieth	JJ	*	-	-	-	-	*	-
en_3322.txt	0	30	century	NN	*))))))))))))	-	-	-	-	*	-
en_3322.txt	0	31	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	1	TB	NN	*	-	-	-	-	*	-
en_3322.txt	0	2	drugs	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	3	currently	RB	(PP(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	4	in	IN	*	-	-	-	-	*	-
en_3322.txt	0	5	use	NN	(NP*)))	-	-	-	-	*	-
en_3322.txt	0	6	were	VBD	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	developed	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	between	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	9	1950	CD	(NP*	-	-	-	-	*	-
en_3322.txt	0	10	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	11	1970	CD	*))))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Indeed	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP*	-	-	-	-	*	(2
en_3322.txt	0	3	Bacille	NNP	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	4	Calmette	NNP	*	-	-	-	-	*	-
en_3322.txt	0	5	–	NNP	*	-	-	-	-	*	-
en_3322.txt	0	6	Guérin	NNP	*)	-	-	-	-	*	-
en_3322.txt	0	7	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_3322.txt	0	8	BCG	NNP	(NP*)	-	-	-	-	*	-
en_3322.txt	0	9	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_3322.txt	0	10	vaccine	NN	*)	-	-	-	-	*	2)
en_3322.txt	0	11	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	12	almost	RB	*	-	-	-	-	*	-
en_3322.txt	0	13	100	CD	(ADJP(NP*	-	-	-	-	*	-
en_3322.txt	0	14	years	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	15	old	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	16	,	,	*	-	-	-	-	*	-
en_3322.txt	0	17	while	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	18	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	19	most	RBS	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	20	widely	RB	*	-	-	-	-	*	-
en_3322.txt	0	21	used	VBN	*)	-	-	-	-	*	-
en_3322.txt	0	22	diagnostic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	23	test	NN	*)	-	-	-	-	*	-
en_3322.txt	0	24	,	,	*	-	-	-	-	*	-
en_3322.txt	0	25	microscopic	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	26	detection	NN	*)	-	-	-	-	*	-
en_3322.txt	0	27	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	28	bacilli	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	29	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	30	sputum	NN	(NP*)))))	-	-	-	-	*	-
en_3322.txt	0	31	,	,	*)	-	-	-	-	*	-
en_3322.txt	0	32	was	VBD	(VP*	-	-	-	-	*	-
en_3322.txt	0	33	developed	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	34	130	CD	(ADVP(NP*	-	-	-	-	*	-
en_3322.txt	0	35	years	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	36	ago	RB	*))))))	-	-	-	-	*	-
en_3322.txt	0	37	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	No	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_3322.txt	0	1	wonder	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	2	that	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	3	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	4	efficacy	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	6	these	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	7	tools	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	8	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	weakened	VBN	(VP*)))))	-	-	-	-	*	-
en_3322.txt	0	10	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(2
en_3322.txt	0	1	current	JJ	*	-	-	-	-	*	-
en_3322.txt	0	2	vaccine	NN	*)	-	-	-	-	*	2)
en_3322.txt	0	3	prevents	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	severe	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	5	TB	NN	*)	-	-	-	-	*	-
en_3322.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	infants	NNS	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	8	,	,	*	-	-	-	-	*	-
en_3322.txt	0	9	but	CC	*	-	-	-	-	*	-
en_3322.txt	0	10	not	RB	*	-	-	-	-	*	-
en_3322.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	12	most	RBS	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	13	prevalent	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	14	pulmonary	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	TB	NN	*)	-	-	-	-	*	-
en_3322.txt	0	16	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	17	all	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	18	age	NN	*	-	-	-	-	*	-
en_3322.txt	0	19	groups	NNS	*)))))))	-	-	-	-	*	-
en_3322.txt	0	20	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(1
en_3322.txt	0	1	microscopic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	2	test	NN	*)	-	-	-	-	*	1)
en_3322.txt	0	3	gives	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	false	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	5	results	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	nearly	RB	(NP(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	8	half	DT	*))	-	-	-	-	*	-
en_3322.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	10	all	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	11	cases	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	We	PRP	(TOP(S(NP*)	-	-	-	-	*	(0)
en_3322.txt	0	1	like	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	2	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	3	think	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	5	TB	NN	(NP*))	-	-	-	-	*	-
en_3322.txt	0	6	as	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	8	malady	NN	*)	-	-	-	-	*	-
en_3322.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	10	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	11	past	NN	*))))))))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	In	IN	(TOP(S(S(PP*	-	-	-	-	*	-
en_3322.txt	0	1	fact	NN	(NP*))	-	-	-	-	*	-
en_3322.txt	0	2	,	,	*	-	-	-	-	*	-
en_3322.txt	0	3	nine	CD	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	4	million	CD	*)	-	-	-	-	*	-
en_3322.txt	0	5	people	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	6	develop	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	the	DT	(NP*	-	-	-	-	*	(3
en_3322.txt	0	8	active	JJ	*	-	-	-	-	*	-
en_3322.txt	0	9	disease	NN	*)	-	-	-	-	*	3)
en_3322.txt	0	10	every	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	11	year	NN	*)))	-	-	-	-	*	-
en_3322.txt	0	12	,	,	*	-	-	-	-	*	-
en_3322.txt	0	13	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	14	one	CD	(S(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	15	in	IN	*	-	-	-	-	*	-
en_3322.txt	0	16	five	CD	*))	-	-	-	-	*	-
en_3322.txt	0	17	will	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	18	die	VB	(VP*)))	-	-	-	-	*	-
en_3322.txt	0	19	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	This	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_3322.txt	0	1	places	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	3	tubercle	JJ	*	-	-	-	-	*	-
en_3322.txt	0	4	bacillus	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	second	JJ	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	6	only	RB	*	-	-	-	-	*	-
en_3322.txt	0	7	to	TO	(PP*	-	-	-	-	*	-
en_3322.txt	0	8	human	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	9	immunodeficiency	JJ	*	-	-	-	-	*	-
en_3322.txt	0	10	virus	NN	*)))	-	-	-	-	*	-
en_3322.txt	0	11	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_3322.txt	0	12	HIV	NNP	(NP*)	-	-	-	-	*	-
en_3322.txt	0	13	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_3322.txt	0	14	on	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	15	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	16	list	NN	*)	-	-	-	-	*	-
en_3322.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	18	top	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	19	microbial	JJ	*	-	-	-	-	*	-
en_3322.txt	0	20	killers	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	21	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	One-third	NN	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	1	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	3	world	NN	*	-	-	-	-	*	-
en_3322.txt	0	4	'	POS	*)	-	-	-	-	*	-
en_3322.txt	0	5	s	JJ	*	-	-	-	-	*	-
en_3322.txt	0	6	population	NN	*)))	-	-	-	-	*	-
en_3322.txt	0	7	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	infected	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	10	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	11	causative	JJ	*	-	-	-	-	*	-
en_3322.txt	0	12	agent	NN	*))	-	-	-	-	*	-
en_3322.txt	0	13	,	,	*	-	-	-	-	*	-
en_3322.txt	0	14	though	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	15	only	RB	(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	16	one	CD	*)	-	-	-	-	*	-
en_3322.txt	0	17	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	18	ten	NN	(NP*)))	-	-	-	-	*	-
en_3322.txt	0	19	develops	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	20	the	DT	(NP*	-	-	-	-	*	(3
en_3322.txt	0	21	active	JJ	*	-	-	-	-	*	-
en_3322.txt	0	22	disease	NN	*))))))	-	-	-	-	*	3)
en_3322.txt	0	23	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_3322.txt	0	1	bad	JJ	*	-	-	-	-	*	-
en_3322.txt	0	2	news	NN	*)	-	-	-	-	*	-
en_3322.txt	0	3	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	that	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	5	infected	JJ	(S(NP*	-	-	-	-	*	(4
en_3322.txt	0	6	individuals	NNS	*)	-	-	-	-	*	4)
en_3322.txt	0	7	carry	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	9	agent	NN	*)	-	-	-	-	*	-
en_3322.txt	0	10	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	11	them	PRP	(NP*))	-	-	-	-	*	(4)
en_3322.txt	0	12	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	their	PRP$	(NP*	-	-	-	-	*	(4)
en_3322.txt	0	14	entire	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	lives	NNS	*)))))))	-	-	-	-	*	-
en_3322.txt	0	16	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	When	WRB	(TOP(S(SBAR(WHADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	one	CD	(S(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	2	'	:	*	-	-	-	-	*	-
en_3322.txt	0	3	s	PRP	(NP*	-	-	-	-	*	(5
en_3322.txt	0	4	immune	JJ	*	-	-	-	-	*	-
en_3322.txt	0	5	system	NN	*))	-	-	-	-	*	5)
en_3322.txt	0	6	weakens	VBZ	(VP*)))	-	-	-	-	*	-
en_3322.txt	0	7	,	,	*	-	-	-	-	*	-
en_3322.txt	0	8	the	DT	(NP*	-	-	-	-	*	(3
en_3322.txt	0	9	disease	NN	*)	-	-	-	-	*	3)
en_3322.txt	0	10	may	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	erupt	VB	(VP*))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	With	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3322.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	2	emergence	NN	*)	-	-	-	-	*	-
en_3322.txt	0	3	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	4	the	DT	(NP(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	5	1980	CD	*	-	-	-	-	*	-
en_3322.txt	0	6	'	POS	*)	-	-	-	-	*	-
en_3322.txt	0	7	s	NN	*)	-	-	-	-	*	-
en_3322.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	9	HIV	NNP	(NP(NP*)	-	-	-	-	*	(6)
en_3322.txt	0	10	,	,	*	-	-	-	-	*	-
en_3322.txt	0	11	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	12	compromises	VBZ	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	13	the	DT	(NP*	-	-	-	-	*	(5
en_3322.txt	0	14	immune	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	system	NN	*))))))))))	-	-	-	-	*	5)
en_3322.txt	0	16	,	,	*	-	-	-	-	*	-
en_3322.txt	0	17	TB	NN	(NP*)	-	-	-	-	*	-
en_3322.txt	0	18	reemerged	VBD	(VP(VP*)	-	-	-	-	*	-
en_3322.txt	0	19	,	,	*	-	-	-	-	*	-
en_3322.txt	0	20	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	21	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	22	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	23	number-one	JJ	*	-	-	-	-	*	-
en_3322.txt	0	24	killer	NN	*)	-	-	-	-	*	-
en_3322.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	26	HIV-infected	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	27	individuals	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	28	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Roughly	RB	(TOP(S(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	1	15	CD	*	-	-	-	-	*	-
en_3322.txt	0	2	million	CD	*)	-	-	-	-	*	-
en_3322.txt	0	3	people	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	4	suffer	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	from	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	6	co-infection	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	8	HIV	NNP	(NP(NP*)	-	-	-	-	*	(6)
en_3322.txt	0	9	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	10	Mycobacterium	NNP	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	11	tuberculosis	NN	*)	-	-	-	-	*	-
en_3322.txt	0	12	,	,	*	-	-	-	-	*	-
en_3322.txt	0	13	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	14	primary	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	causative	NN	*	-	-	-	-	*	-
en_3322.txt	0	16	agent	NN	*))))))	-	-	-	-	*	-
en_3322.txt	0	17	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	18	most	JJS	(NP*	-	-	-	-	*	-
en_3322.txt	0	19	TB	NN	*	-	-	-	-	*	-
en_3322.txt	0	20	cases	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	21	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Moreover	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	3	tubercle	JJ	*	-	-	-	-	*	-
en_3322.txt	0	4	bacillus	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	engages	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	trench	NN	(NP*	-	-	-	-	*	-
en_3322.txt	0	8	warfare	NN	*))	-	-	-	-	*	-
en_3322.txt	0	9	,	,	*	-	-	-	-	*	-
en_3322.txt	0	10	gaining	VBG	(S(VP(VP*	-	-	-	-	*	-
en_3322.txt	0	11	resistance	NN	(NP*)	-	-	-	-	*	-
en_3322.txt	0	12	to	TO	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	conventional	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	14	antibiotics	NNS	*	-	-	-	-	*	-
en_3322.txt	0	15	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	16	canonical	JJ	*	-	-	-	-	*	-
en_3322.txt	0	17	vaccination	NN	*	-	-	-	-	*	-
en_3322.txt	0	18	approaches	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	19	,	,	*	-	-	-	-	*	-
en_3322.txt	0	20	as	RB	(CONJP*	-	-	-	-	*	-
en_3322.txt	0	21	well	RB	*	-	-	-	-	*	-
en_3322.txt	0	22	as	IN	*)	-	-	-	-	*	-
en_3322.txt	0	23	delaying	VBG	(VP*	-	-	-	-	*	-
en_3322.txt	0	24	diagnosis	NN	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	25	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	26	determination	NN	*)	-	-	-	-	*	-
en_3322.txt	0	27	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	28	drug	NN	(NP*	-	-	-	-	*	-
en_3322.txt	0	29	sensitivity	NN	*)))))))	-	-	-	-	*	-
en_3322.txt	0	30	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Whereas	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_3322.txt	0	1	pandemics	NNS	(S(NP*)	-	-	-	-	*	-
en_3322.txt	0	2	appear	VBP	(VP(VP*	-	-	-	-	*	-
en_3322.txt	0	3	suddenly	RB	(ADVP*))	-	-	-	-	*	-
en_3322.txt	0	4	,	,	*	-	-	-	-	*	-
en_3322.txt	0	5	spread	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	6	rapidly	RB	(ADVP*))	-	-	-	-	*	-
en_3322.txt	0	7	,	,	*	-	-	-	-	*	-
en_3322.txt	0	8	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	9	raise	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	enormous	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	11	fears	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	an	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	14	impending	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	threat	NN	*)))))))	-	-	-	-	*	-
en_3322.txt	0	16	,	,	*	-	-	-	-	*	-
en_3322.txt	0	17	TB	NN	(NP*)	-	-	-	-	*	-
en_3322.txt	0	18	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	19	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	20	spreading	VBG	(VP*	-	-	-	-	*	-
en_3322.txt	0	21	slowly	RB	(ADVP*	-	-	-	-	*	-
en_3322.txt	0	22	but	CC	*	-	-	-	-	*	-
en_3322.txt	0	23	consistently	RB	*)	-	-	-	-	*	-
en_3322.txt	0	24	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	25	tens	NNS	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	26	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	27	thousands	NNS	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	28	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	29	years	NNS	(NP*))))))	-	-	-	-	*	-
en_3322.txt	0	30	,	,	*	-	-	-	-	*	-
en_3322.txt	0	31	patiently	RB	(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	32	waiting	VBG	(VP*	-	-	-	-	*	-
en_3322.txt	0	33	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	34	new	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	35	opportunities	NNS	*)))))))	-	-	-	-	*	-
en_3322.txt	0	36	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Treatment	NNP	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	1	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	2	TB	NN	(NP*)))	-	-	-	-	*	-
en_3322.txt	0	3	requires	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	5	minimum	NN	*)	-	-	-	-	*	-
en_3322.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	three	CD	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	8	drugs	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	9	administered	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	over	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	11	at	IN	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	12	least	JJS	*	-	-	-	-	*	-
en_3322.txt	0	13	six	CD	*)	-	-	-	-	*	-
en_3322.txt	0	14	months	NNS	*)))))))	-	-	-	-	*	-
en_3322.txt	0	15	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Compare	VB	(TOP(S(VP*	-	-	-	-	*	-
en_3322.txt	0	1	this	DT	(NP*)	-	-	-	-	*	-
en_3322.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	3	antibiotic	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	4	treatment	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	6	,	,	(PRN*	-	-	-	-	*	-
en_3322.txt	0	7	say	VB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	8	,	,	*)	-	-	-	-	*	-
en_3322.txt	0	9	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	10	urogenital	JJ	*	-	-	-	-	*	-
en_3322.txt	0	11	infection	NN	*)	-	-	-	-	*	-
en_3322.txt	0	12	,	,	*	-	-	-	-	*	-
en_3322.txt	0	13	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	14	lasts	VBZ	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	15	a	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	16	few	JJ	*	-	-	-	-	*	-
en_3322.txt	0	17	weeks	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	18	at	IN	(ADVP*	-	-	-	-	*	-
en_3322.txt	0	19	most	JJS	*)))))))))	-	-	-	-	*	-
en_3322.txt	0	20	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_3322.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	2	result	NN	*))	-	-	-	-	*	-
en_3322.txt	0	3	,	,	*	-	-	-	-	*	-
en_3322.txt	0	4	compliance	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	5	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	6	TB	NN	(NP*	-	-	-	-	*	-
en_3322.txt	0	7	drug	NN	*	-	-	-	-	*	-
en_3322.txt	0	8	treatment	NN	*)))	-	-	-	-	*	-
en_3322.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	particularly	RB	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	11	weak	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	12	,	,	*	-	-	-	-	*	-
en_3322.txt	0	13	paving	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	15	way	NN	*)	-	-	-	-	*	-
en_3322.txt	0	16	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	17	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	18	emergence	NN	*)	-	-	-	-	*	-
en_3322.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	20	multidrug-resistant	JJ	(NP(ADJP(ADJP*)	-	-	-	-	*	-
en_3322.txt	0	21	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_3322.txt	0	22	MDR	NNP	(NP*)	-	-	-	-	*	-
en_3322.txt	0	23	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_3322.txt	0	24	TB	NN	*))	-	-	-	-	*	-
en_3322.txt	0	25	,	,	*	-	-	-	-	*	-
en_3322.txt	0	26	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	27	can	MD	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	28	no	RB	(ADVP*	-	-	-	-	*	-
en_3322.txt	0	29	longer	RB	*)	-	-	-	-	*	-
en_3322.txt	0	30	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	31	treated	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	32	by	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	33	conventional	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	34	therapeutic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	35	regimes	NNS	*)))))))))))))	-	-	-	-	*	-
en_3322.txt	0	36	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Some	RB	(TOP(S(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	1	50	CD	*	-	-	-	-	*	-
en_3322.txt	0	2	million	CD	*)	-	-	-	-	*	-
en_3322.txt	0	3	people	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	infected	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	6	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	tubercle	NN	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	8	bacilli	NN	*)	-	-	-	-	*	-
en_3322.txt	0	9	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	10	are	VBP	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	11	MDR	JJ	(ADJP*))))))))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	While	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_3322.txt	0	1	treating	VBG	(S(S(VP*	-	-	-	-	*	-
en_3322.txt	0	2	MDR-TB	NNP	(NP*)))	-	-	-	-	*	(7)
en_3322.txt	0	3	remains	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	possible	JJ	(ADJP*))))	-	-	-	-	*	-
en_3322.txt	0	5	,	,	*	-	-	-	-	*	-
en_3322.txt	0	6	doing	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	7	so	RB	(ADVP*)))	-	-	-	-	*	-
en_3322.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	arduous	JJ	(ADJP*)	-	-	-	-	*	-
en_3322.txt	0	10	,	,	*	-	-	-	-	*	-
en_3322.txt	0	11	with	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	12	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	13	treatment	NN	*	-	-	-	-	*	-
en_3322.txt	0	14	time	NN	*)	-	-	-	-	*	-
en_3322.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	16	roughly	RB	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	17	two	CD	*)	-	-	-	-	*	-
en_3322.txt	0	18	years	NNS	*))))	-	-	-	-	*	-
en_3322.txt	0	19	,	,	*	-	-	-	-	*	-
en_3322.txt	0	20	using	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	21	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	22	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	23	are	VBP	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	24	neither	CC	(UCP*	-	-	-	-	*	-
en_3322.txt	0	25	as	RB	(PP*	-	-	-	-	*	-
en_3322.txt	0	26	efficient	JJ	(ADJP(ADJP*)	-	-	-	-	*	-
en_3322.txt	0	27	nor	CC	*	-	-	-	-	*	-
en_3322.txt	0	28	as	RB	(ADJP(ADJP*	-	-	-	-	*	-
en_3322.txt	0	29	benign	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	30	as	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	31	canonical	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	32	drugs	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	33	–	SYM	(X*)	-	-	-	-	*	-
en_3322.txt	0	34	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	35	at	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	36	a	DT	(NP(NP*	-	-	-	-	*	(8
en_3322.txt	0	37	cost	NN	*)	-	-	-	-	*	-
en_3322.txt	0	38	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	39	rises	VBZ	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	40	by	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	41	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	42	factor	NN	*)	-	-	-	-	*	-
en_3322.txt	0	43	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	44	10-100	CD	(NP*)))))))))))))))))	-	-	-	-	*	8)
en_3322.txt	0	45	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	While	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_3322.txt	0	1	this	DT	(S(NP*	-	-	-	-	*	(8
en_3322.txt	0	2	additional	JJ	*	-	-	-	-	*	-
en_3322.txt	0	3	cost	NN	*)	-	-	-	-	*	8)
en_3322.txt	0	4	can	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	6	borne	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	by	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	8	health-care	NN	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	9	systems	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	11	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	12	rich	JJ	*	-	-	-	-	*	-
en_3322.txt	0	13	world	NN	*)))))))))	-	-	-	-	*	-
en_3322.txt	0	14	,	,	*	-	-	-	-	*	-
en_3322.txt	0	15	it	PRP	(NP*)	-	-	-	-	*	(8)
en_3322.txt	0	16	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	17	excessive	JJ	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	18	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	19	poor	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	20	countries	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	21	,	,	*	-	-	-	-	*	-
en_3322.txt	0	22	implying	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	23	no	DT	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	24	,	,	*	-	-	-	-	*	-
en_3322.txt	0	25	or	CC	*	-	-	-	-	*	-
en_3322.txt	0	26	insufficient	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	27	,	,	*	-	-	-	-	*	-
en_3322.txt	0	28	treatment	NN	*)))))	-	-	-	-	*	-
en_3322.txt	0	29	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Moreover	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	3	85	CD	(NP*	-	-	-	-	*	-
en_3322.txt	0	4	countries	NNS	*))	-	-	-	-	*	-
en_3322.txt	0	5	,	,	*	-	-	-	-	*	-
en_3322.txt	0	6	extensively	RB	(NP(NP(ADJP*	-	-	-	-	*	-
en_3322.txt	0	7	drug-resistant	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	8	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_3322.txt	0	9	XDR	NNP	(NP*)	-	-	-	-	*	-
en_3322.txt	0	10	-RRB-	-RRB-	*)	-	-	-	-	*	-
en_3322.txt	0	11	TB	NN	*)	-	-	-	-	*	-
en_3322.txt	0	12	,	,	*	-	-	-	-	*	-
en_3322.txt	0	13	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	14	is	VBZ	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	15	virtually	RB	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	16	untreatable	JJ	*))))	-	-	-	-	*	-
en_3322.txt	0	17	,	,	*)	-	-	-	-	*	-
en_3322.txt	0	18	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	19	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	20	diagnosed	VBN	(VP*)))	-	-	-	-	*	-
en_3322.txt	0	21	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Indeed	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	surgical	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	3	resection	NN	*)	-	-	-	-	*	-
en_3322.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	5	affected	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	6	lungs	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	7	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	become	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	10	treatment	NN	*)	-	-	-	-	*	-
en_3322.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	12	choice	NN	(NP*)))	-	-	-	-	*	-
en_3322.txt	0	13	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	14	many	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	15	XDR-TB	JJ	*	-	-	-	-	*	-
en_3322.txt	0	16	hotspots	NNS	*))))	-	-	-	-	*	-
en_3322.txt	0	17	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Welcome	UH	(TOP(INTJ*	-	-	-	-	*	-
en_3322.txt	0	1	back	RB	(PP(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	2	to	TO	*	-	-	-	-	*	-
en_3322.txt	0	3	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	4	pre-antibiotic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	5	era	NN	*))	-	-	-	-	*	-
en_3322.txt	0	6	!	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	So	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	3	question	NN	*)	-	-	-	-	*	-
en_3322.txt	0	4	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	not	RB	*	-	-	-	-	*	-
en_3322.txt	0	6	whether	IN	(SBAR(SBAR*	-	-	-	-	*	-
en_3322.txt	0	7	we	PRP	(S(NP*)	-	-	-	-	*	-
en_3322.txt	0	8	need	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	novel	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	10	drugs	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	11	,	,	*	-	-	-	-	*	-
en_3322.txt	0	12	vaccines	NNS	(NP*)	-	-	-	-	*	(9)
en_3322.txt	0	13	,	,	*	-	-	-	-	*	-
en_3322.txt	0	14	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	15	diagnostics	NNS	(NP*)))))	-	-	-	-	*	-
en_3322.txt	0	16	,	,	*	-	-	-	-	*	-
en_3322.txt	0	17	but	CC	*	-	-	-	-	*	-
en_3322.txt	0	18	when	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_3322.txt	0	19	they	PRP	(S(NP*)	-	-	-	-	*	(9)
en_3322.txt	0	20	will	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	21	become	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	22	available	JJ	(ADJP*)))))))	-	-	-	-	*	-
en_3322.txt	0	23	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(10
en_3322.txt	0	1	new	JJ	*	-	-	-	-	*	-
en_3322.txt	0	2	GeneXpert	NNP	*	-	-	-	-	*	-
en_3322.txt	0	3	test	NN	*)	-	-	-	-	*	10)
en_3322.txt	0	4	diagnoses	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	not	RB	(NP(CONJP*	-	-	-	-	*	-
en_3322.txt	0	6	only	RB	*)	-	-	-	-	*	-
en_3322.txt	0	7	TB	NN	(NP*)	-	-	-	-	*	-
en_3322.txt	0	8	,	,	*	-	-	-	-	*	-
en_3322.txt	0	9	but	CC	(CONJP*	-	-	-	-	*	-
en_3322.txt	0	10	also	RB	*)	-	-	-	-	*	-
en_3322.txt	0	11	,	,	(PRN*	-	-	-	-	*	-
en_3322.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	14	same	JJ	*	-	-	-	-	*	-
en_3322.txt	0	15	step	NN	*))	-	-	-	-	*	-
en_3322.txt	0	16	,	,	*)	-	-	-	-	*	-
en_3322.txt	0	17	MDR-TB	NNP	(NP(NP*)	-	-	-	-	*	(7|(7)
en_3322.txt	0	18	,	,	*	-	-	-	-	*	-
en_3322.txt	0	19	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_3322.txt	0	20	means	VBZ	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	21	that	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	22	it	PRP	(S(NP*)	-	-	-	-	*	(10)
en_3322.txt	0	23	can	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	24	rapidly	RB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	25	direct	VB	(VP(VP*	-	-	-	-	*	-
en_3322.txt	0	26	adequate	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	27	treatment	NN	*))	-	-	-	-	*	-
en_3322.txt	0	28	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	29	prevent	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	30	infection	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	31	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	32	contacts	NNS	(NP*))))	-	-	-	-	*	-
en_3322.txt	0	33	–	SYM	(FRAG(X*)	-	-	-	-	*	-
en_3322.txt	0	34	a	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	35	true	JJ	*	-	-	-	-	*	-
en_3322.txt	0	36	breakthrough	NN	*))))))))))))	-	-	-	-	*	7)
en_3322.txt	0	37	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Unfortunately	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP*	-	-	-	-	*	(10
en_3322.txt	0	3	test	NN	*)	-	-	-	-	*	10)
en_3322.txt	0	4	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	expensive	JJ	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	6	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	7	sophisticated	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	8	,	,	*	-	-	-	-	*	-
en_3322.txt	0	9	putting	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	10	it	PRP	(NP*)	-	-	-	-	*	(10)
en_3322.txt	0	11	out	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	13	reach	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	14	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	15	many	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	16	poor	JJ	*	-	-	-	-	*	-
en_3322.txt	0	17	countries	NNS	*))))))))	-	-	-	-	*	-
en_3322.txt	0	18	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	A	DT	(TOP(S(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	1	number	NN	*)	-	-	-	-	*	-
en_3322.txt	0	2	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	3	other	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	4	drugs	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	5	–	SYM	(X(X*)	-	-	-	-	*	-
en_3322.txt	0	6	some	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	7	new	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	8	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	9	some	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	10	repurposed	JJ	*	-	-	-	-	*	-
en_3322.txt	0	11	–	NN	*))))))	-	-	-	-	*	-
en_3322.txt	0	12	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	13	currently	RB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	15	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	16	last	JJ	*	-	-	-	-	*	-
en_3322.txt	0	17	stage	NN	*)	-	-	-	-	*	-
en_3322.txt	0	18	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	19	clinical	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	20	trials	NNS	*))))))	-	-	-	-	*	-
en_3322.txt	0	21	,	,	*	-	-	-	-	*	-
en_3322.txt	0	22	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	23	one	CD	(S(NP*	-	-	-	-	*	-
en_3322.txt	0	24	new	JJ	*	-	-	-	-	*	-
en_3322.txt	0	25	drug	NN	*)	-	-	-	-	*	-
en_3322.txt	0	26	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	27	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	28	approved	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	29	by	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	30	US	NNP	(NP*	-	-	-	-	*	-
en_3322.txt	0	31	regulators	NNS	*))	-	-	-	-	*	-
en_3322.txt	0	32	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	33	treatment	NN	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	34	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	35	MDR-TB	NNP	(NP*))))	-	-	-	-	*	(7)
en_3322.txt	0	36	even	RB	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	37	before	IN	*	-	-	-	-	*	-
en_3322.txt	0	38	such	JJ	(S(NP*	-	-	-	-	*	-
en_3322.txt	0	39	trials	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	40	have	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	41	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	42	completed	VBN	(VP*)))))))))	-	-	-	-	*	-
en_3322.txt	0	43	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_3322.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	2	first	JJ	*	-	-	-	-	*	-
en_3322.txt	0	3	potential	JJ	*	-	-	-	-	*	-
en_3322.txt	0	4	vaccine	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_3322.txt	0	6	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	tested	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	9	efficacy	NN	(NP*))))))))	-	-	-	-	*	-
en_3322.txt	0	10	recently	RB	(VP(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	11	failed	VBD	*	-	-	-	-	*	-
en_3322.txt	0	12	miserably	RB	(ADVP*))	-	-	-	-	*	-
en_3322.txt	0	13	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	So	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	3	good	JJ	*	-	-	-	-	*	-
en_3322.txt	0	4	news	NN	*)	-	-	-	-	*	-
en_3322.txt	0	5	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	6	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	7	last	JJ	*	-	-	-	-	*	-
en_3322.txt	0	8	decade	NN	*)))	-	-	-	-	*	-
en_3322.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	just	RB	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	11	a	DT	*	-	-	-	-	*	-
en_3322.txt	0	12	glimmer	NN	*)	-	-	-	-	*	-
en_3322.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	14	hope	NN	(NP*))))	-	-	-	-	*	-
en_3322.txt	0	15	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	We	PRP	(TOP(S(S(NP*)	-	-	-	-	*	(11)
en_3322.txt	0	1	still	RB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	2	have	VBP	(VP(VP*	-	-	-	-	*	-
en_3322.txt	0	3	a	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	4	long	JJ	*	-	-	-	-	*	-
en_3322.txt	0	5	way	NN	*	-	-	-	-	*	-
en_3322.txt	0	6	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	7	go	VB	(VP*)))))	-	-	-	-	*	-
en_3322.txt	0	8	,	,	*	-	-	-	-	*	-
en_3322.txt	0	9	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	10	accelerated	VBD	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	R	NNP	(NP*	-	-	-	-	*	(12
en_3322.txt	0	12	&	CC	*	-	-	-	-	*	-
en_3322.txt	0	13	D	NNP	*)	-	-	-	-	*	12)
en_3322.txt	0	14	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	15	develop	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	16	new	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	17	drugs	NNS	*)))))))	-	-	-	-	*	-
en_3322.txt	0	18	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	19	vaccines	NNS	(S(NP*)	-	-	-	-	*	-
en_3322.txt	0	20	can	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	21	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	22	achieved	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	23	only	RB	(PP*	-	-	-	-	*	-
en_3322.txt	0	24	with	IN	*	-	-	-	-	*	-
en_3322.txt	0	25	increased	VBN	(NP*	-	-	-	-	*	-
en_3322.txt	0	26	funding	NN	*))))))	-	-	-	-	*	-
en_3322.txt	0	27	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Unfortunately	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	1	,	,	*	-	-	-	-	*	-
en_3322.txt	0	2	private-sector	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	3	incentives	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	4	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	5	developing	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	6	new	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	7	TB	NN	*	-	-	-	-	*	-
en_3322.txt	0	8	interventions	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	9	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	too	RB	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	11	weak	JJ	*))	-	-	-	-	*	-
en_3322.txt	0	12	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	New	JJ	(TOP(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	1	approaches	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	2	,	,	*	-	-	-	-	*	-
en_3322.txt	0	3	such	JJ	(PP*	-	-	-	-	*	-
en_3322.txt	0	4	as	IN	*	-	-	-	-	*	-
en_3322.txt	0	5	partnerships	NNS	(NP(NP*)	-	-	-	-	*	-
en_3322.txt	0	6	between	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	public	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	8	research	NN	*	-	-	-	-	*	-
en_3322.txt	0	9	institutions	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	10	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	11	private	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	12	industry	NN	*)))))	-	-	-	-	*	-
en_3322.txt	0	13	,	,	*)	-	-	-	-	*	-
en_3322.txt	0	14	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	15	needed	VBN	(VP*))	-	-	-	-	*	-
en_3322.txt	0	16	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	While	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_3322.txt	0	1	clinical	JJ	(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	2	trials	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	4	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	5	most	RBS	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	6	promising	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	7	drugs	NNS	*	-	-	-	-	*	-
en_3322.txt	0	8	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	9	vaccines	NNS	*)))	-	-	-	-	*	-
en_3322.txt	0	10	need	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	13	pursued	VBN	(VP*)))))))	-	-	-	-	*	-
en_3322.txt	0	14	,	,	*	-	-	-	-	*	-
en_3322.txt	0	15	we	PRP	(NP*)	-	-	-	-	*	-
en_3322.txt	0	16	also	RB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	17	need	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	18	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	19	go	VB	(VP(VP*	-	-	-	-	*	-
en_3322.txt	0	20	back	RB	(ADVP*	-	-	-	-	*	-
en_3322.txt	0	21	to	TO	(PP*	-	-	-	-	*	-
en_3322.txt	0	22	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	23	drawing	NN	*	-	-	-	-	*	-
en_3322.txt	0	24	board	NN	*))))	-	-	-	-	*	-
en_3322.txt	0	25	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	26	develop	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	27	entirely	RB	(ADVP*))	-	-	-	-	*	-
en_3322.txt	0	28	new	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	29	tactics	NNS	*)))))	-	-	-	-	*	-
en_3322.txt	0	30	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	Current	JJ	(TOP(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	1	annual	JJ	*	-	-	-	-	*	-
en_3322.txt	0	2	funding	NN	*)	-	-	-	-	*	-
en_3322.txt	0	3	for	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	4	R	NNP	(NP*	-	-	-	-	*	(12
en_3322.txt	0	5	&	CC	*	-	-	-	-	*	-
en_3322.txt	0	6	D	NNP	*))	-	-	-	-	*	12)
en_3322.txt	0	7	devoted	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	to	TO	(PP*	-	-	-	-	*	-
en_3322.txt	0	9	TB	NN	(NP*))))	-	-	-	-	*	-
en_3322.txt	0	10	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	estimated	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	12	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	13	be	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	14	$	$	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	15	500	CD	*	-	-	-	-	*	-
en_3322.txt	0	16	million	CD	*)))))))	-	-	-	-	*	-
en_3322.txt	0	17	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_3322.txt	0	1	more	JJR	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	2	than	IN	*	-	-	-	-	*	-
en_3322.txt	0	3	$	$	*	-	-	-	-	*	-
en_3322.txt	0	4	2	CD	*	-	-	-	-	*	-
en_3322.txt	0	5	billion	CD	*))	-	-	-	-	*	-
en_3322.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	needed	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	8	annually	RB	(ADVP*)))	-	-	-	-	*	-
en_3322.txt	0	9	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	That	DT	(TOP(S(S(NP*	-	-	-	-	*	(13
en_3322.txt	0	1	amount	NN	*)	-	-	-	-	*	13)
en_3322.txt	0	2	may	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	3	seem	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	4	unrealistically	RB	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	5	high	JJ	*))))	-	-	-	-	*	-
en_3322.txt	0	6	,	,	*	-	-	-	-	*	-
en_3322.txt	0	7	but	CC	*	-	-	-	-	*	-
en_3322.txt	0	8	it	PRP	(S(NP*)	-	-	-	-	*	(13)
en_3322.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	a	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	11	negligible	JJ	*	-	-	-	-	*	-
en_3322.txt	0	12	proportion	NN	*)	-	-	-	-	*	-
en_3322.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	15	estimated	VBN	(QP*	-	-	-	-	*	-
en_3322.txt	0	16	$	$	*	-	-	-	-	*	-
en_3322.txt	0	17	160	CD	*	-	-	-	-	*	-
en_3322.txt	0	18	billion	CD	*))	-	-	-	-	*	-
en_3322.txt	0	19	spent	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	20	on	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	21	health-related	JJ	(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	22	R	NN	*)	-	-	-	-	*	-
en_3322.txt	0	23	&	CC	*	-	-	-	-	*	-
en_3322.txt	0	24	D	NNP	(NP*	-	-	-	-	*	-
en_3322.txt	0	25	worldwide	NN	*)))))))))	-	-	-	-	*	-
en_3322.txt	0	26	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	More	RBR	(TOP(FRAG(ADJP*	-	-	-	-	*	-
en_3322.txt	0	1	important	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	2	,	,	*	-	-	-	-	*	-
en_3322.txt	0	3	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_3322.txt	0	4	economic	JJ	*	-	-	-	-	*	-
en_3322.txt	0	5	burden	NN	*)	-	-	-	-	*	-
en_3322.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	7	TB	NN	(NP*)))	-	-	-	-	*	-
en_3322.txt	0	8	has	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	been	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	10	put	VBN	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	as	RB	(ADVP(ADVP*	-	-	-	-	*	-
en_3322.txt	0	12	high	JJ	*)	-	-	-	-	*	-
en_3322.txt	0	13	as	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	14	$	$	(NP(QP*	-	-	-	-	*	-
en_3322.txt	0	15	20	CD	*	-	-	-	-	*	-
en_3322.txt	0	16	billion	CD	*))))	-	-	-	-	*	-
en_3322.txt	0	17	annually	RB	(ADVP*)))))	-	-	-	-	*	-
en_3322.txt	0	18	–	SYM	(X*)	-	-	-	-	*	-
en_3322.txt	0	19	and	CC	*	-	-	-	-	*	-
en_3322.txt	0	20	even	RB	(FRAG(ADVP*	-	-	-	-	*	-
en_3322.txt	0	21	higher	RBR	*))	-	-	-	-	*	-
en_3322.txt	0	22	if	IN	(SBAR*	-	-	-	-	*	-
en_3322.txt	0	23	the	DT	(S(NP(NP*	-	-	-	-	*	(14
en_3322.txt	0	24	losses	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	25	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	26	human	JJ	(NP*	-	-	-	-	*	-
en_3322.txt	0	27	capital	NN	*)))	-	-	-	-	*	14)
en_3322.txt	0	28	are	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	29	included	VBN	(VP*))))	-	-	-	-	*	-
en_3322.txt	0	30	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	If	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_3322.txt	0	1	we	PRP	(S(NP*)	-	-	-	-	*	(11)
en_3322.txt	0	2	choose	VBP	(VP*	-	-	-	-	*	-
en_3322.txt	0	3	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	4	continue	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	5	suffering	VBG	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	6	these	DT	(NP*	-	-	-	-	*	(14
en_3322.txt	0	7	losses	NNS	*)))))))))	-	-	-	-	*	14)
en_3322.txt	0	8	,	,	*	-	-	-	-	*	-
en_3322.txt	0	9	we	PRP	(NP*)	-	-	-	-	*	(11)
en_3322.txt	0	10	might	MD	(VP*	-	-	-	-	*	-
en_3322.txt	0	11	save	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	12	some	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	13	money	NN	*)	-	-	-	-	*	-
en_3322.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_3322.txt	0	15	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	16	short	JJ	*	-	-	-	-	*	-
en_3322.txt	0	17	term	NN	*))))	-	-	-	-	*	-
en_3322.txt	0	18	.	.	*))	-	-	-	-	*	-

en_3322.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_3322.txt	0	1	wiser	JJR	*	-	-	-	-	*	-
en_3322.txt	0	2	course	NN	*)	-	-	-	-	*	-
en_3322.txt	0	3	,	,	*	-	-	-	-	*	-
en_3322.txt	0	4	however	RB	(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	5	,	,	*	-	-	-	-	*	-
en_3322.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_3322.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_3322.txt	0	8	make	VB	(VP*	-	-	-	-	*	-
en_3322.txt	0	9	the	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	10	necessary	JJ	*	-	-	-	-	*	-
en_3322.txt	0	11	investments	NNS	*)	-	-	-	-	*	-
en_3322.txt	0	12	today	NN	(NP*)	-	-	-	-	*	-
en_3322.txt	0	13	,	,	*	-	-	-	-	*	-
en_3322.txt	0	14	thereby	RB	(S(ADVP*)	-	-	-	-	*	-
en_3322.txt	0	15	averting	VBG	(VP*	-	-	-	-	*	-
en_3322.txt	0	16	a	DT	(NP*	-	-	-	-	*	-
en_3322.txt	0	17	much	RB	(ADJP*	-	-	-	-	*	-
en_3322.txt	0	18	larger	JJR	*)	-	-	-	-	*	-
en_3322.txt	0	19	bill	NN	*)	-	-	-	-	*	-
en_3322.txt	0	20	tomorrow	NN	(NP*)))))))	-	-	-	-	*	-
en_3322.txt	0	21	.	.	*))	-	-	-	-	*	-

#end document
